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Abstract 
 
 
Background: Breast cancer recurrence is a major clinical event and represents a principal cause of 
breast cancer related death. A discordance rate between receptor status of primary and matched 
recurrence tumours has been reported in the literature but the extent of this in our population is 
unknown. Repeating Immuno-histochemistry (IHC) and fluorescent in-situ hybridization (FISH) 
studies have financial and workforce implications in a resource-constrained environment. However, 
the results of these receptor studies have prognostic implications. Therefore it is important to 
determine the extent of change in receptors in the recurrence. 
Aim: To compare the hormone receptor profile between breast cancer primary and matched loco-
regional recurrence and to ascertain the extent of receptor discordance. 
Methods:  All patients who presented to the respective breast care facilities for breast cancer 
recurrences between 2006 and 2014 were identified using the mammography department records. The 
specimens for each patient were scrutinized. Oestrogen receptor (ER) and progesterone receptor 
(PgR) status as well as the Human Epidermal growth factor type 2 receptor (HER2) receptor statuses 
were noted for each patient and a comparison was made between primary and matching recurrence, 
with loss and gain being noted.  
Results: In the analysis, significant discordance was found for matching hormone receptor status. 
Discordance in oestrogen receptor status occurred in 14.3% of cases: change occurred both from ER-
positive to -negative and vice versa. For progesterone receptor status this occurred in 25.7% of cases. 
A discordance of 14.8% was noted for HER2 receptor status. These results are not dissimilar to what 
has been previously reported in the literature. Of note, adverse receptor discordance: positive to 
negative was noted in a total of 19 receptors (ER 4; PgR 11; HER2 4) 
Conclusion: These results confirm the phenomenon of receptor discordance between breast cancer 
primary and recurrence.  The results support the necessity of confirming receptor status on all loco-
regional recurrent disease. This reinforces the importance of obtaining a confirmatory biopsy in 
patients where recurrence is suspected and therefore allowing the appropriate targeted therapy to be 
selected.  
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    Chapter 1 
Introduction 
 
In South Africa, according to the 2005 cancer registry breast cancer is the most commonly diagnosed 
cancer among women, with a lifetime risk of 1:33. 
Breast cancer recurrence is a serious event and represents a cause of breast cancer related death (1). 
20% to 30% of the patients with early breast cancer will eventually relapse (2). In particular, breast 
cancer patients with loco-regional recurrence have been found to have 5-year disease-free survival 
rates of 13%–37% and overall survival rates of 21%–50% respectively (3-5).  
Women, regardless of their racial or ethnic origin, are at risk of developing breast cancer. Variations 
in breast carcinoma incidence rates among multicultural populations suggest that etiologic factors 
differ in their expression and impact on disease outcome (6). The most significant risk factors  for 
breast cancer development are gender (female gender), age and female hormone exposure (7).  
Gender is the most important factor, with a female to male ratio of 100:1 (7). The incidence of breast 
cancer increases rapidly after the 4
th
 decade and after menopause the incidence continues to increase 
but at a much slower rate peaking in the 5
th
 and 6
th
 decades and then slowly levelling off (7). Family 
history of breast cancer is known to increase the risk of breast cancer. The overall risk depends on the 
number of relatives, their ages at diagnosis and whether the disease was unilateral or bilateral (7).  
A pattern of recurrence between different breast cancer subtypes has been suggested, and it appears 
that ER-negative breast cancers are associated with a higher risk of recurrence during the initial 5 
years after diagnosis, compared to ER-positive breast cancers (8,9).  
Apart from hormone receptor status other risk factors associated with loco-regional recurrence include 
the size of tumour, margin involvement at excision, axillary lymph node status and the nuclear grade 
and differentiation of the tumour.(10) 
The mainstay of treatment for breast cancer is the complete surgical resection with negative margins 
(11). Apart from surgical resection, adjuvant treatment modalities are used to treat micro-metastatic 
disease and are aimed at reducing the risk of recurrence, and reducing breast cancer-related morbidity 
and mortality (12, 13). Adjuvant treatment modalities include radiation, cytotoxic therapy and 
treatment targeting receptors within cancer cells.  
In the case of hormonal treatment, knowledge of the oestrogen(ER) and progesterone (PgR) receptor 
status, as well as the Human Epidermal Growth factor type 2 receptor (HER2) statuses is fundamental 
to treatment selection for both patients with early stage disease and those with recurrent disease.  
In ER-positive early-stage breast cancer, hormone therapy plays a major role in adjuvant treatment, 
either alone or in combination with chemotherapy. Hormone treatments function to decrease 
oestrogen's ability to stimulate existing micro-metastases or dormant cancer cells (14).   
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In the past, the receptor profile of the primary was a guide to both 1
st
 and to 2
nd
 line therapies. For the 
recurrence recent studies have demonstrated that discordance may exist between primary and matched 
recurrence so that therapy chosen for the primary disease may be inappropriate for the recurrence. 
The study by Lindstrom et al demonstrated discordance between the receptor status of primary and 
matched recurrence of 32.4%, 40.7%, and 14.5% for ER, PgR and HER2 respectively (15).  
This finding may mean that a primary tumour which was initially sensitive to hormonal treatment may 
develop a recurrence which lacks hormone receptors and therefore rule out hormonal therapy as a 
treatment option. Conversely, if a recurrence “switched” from receptor negative to receptor positive 
this would justify the use of adjuvant anti-oestrogen therapy. 
Another important observation regarding receptor change was noted by Dieci et Al (16). These 
authors demonstrated that patients who experienced loss of receptor sensitivity at recurrence 
experienced both shorter post recurrence survival and overall survival when compared with 
concordant receptor profiles.  
Tissue confirmation of recurrent breast cancer is recommended by international guidelines (17).  
Preliminary data indicates that the change of the molecular subtype in the recurrent breast cancer can 
prompt clinicians to alter the treatment choice in up to 14% of cases (18, 19-21).  
The aim of this study is to compare the hormone receptor status between breast cancer primary and 
matched loco-regional recurrence in South African women treated at two breast centres associated 
with the University of the Witwatersrand over eight years. The outcomes relating to a change in the 
receptor profile of the recurrent cancer are noted and will be discussed. 
    Chapter 2 
 
Methods 
Ethical approval to undertake the study was obtained from the University of the Witwatersrand 
Human Research Ethics Committee, ethics clearance number M150771 (Appendix 1). 
All patients attending the mammogram facilities at Charlotte Maxeke Johannesburg Academic 
Hospital (CMAH) and Helen Joseph Hospital (HJH) are entered into a filing system with a brief 
history, clinical description and the reason for investigation being noted on a request page. If a 
suspicious lesion is found on mammogram and ultrasound, a mandatory biopsy is performed and a 
biopsy/specimen number is attached to the patient request page. All these request pages were checked, 
beginning in 2006, and all patients with a history or suspicion of a clinical recurrence and subsequent 
biopsy were selected. Based on the four months spent working at the Helen Joseph Breast ward an 
estimate of between 40 and 70 patients will be accrued. This is in keeping with the incidence of 
between 2 and 5% loco-regional recurrence within 5 years. 2874 patients were identified at both 
centres over the 8 years. 
All breast biopsies are done via image guidance, which meant that there should be no side 
room/examination room breast mass biopsies performed. If a suspicious mass is found at examination, 
the patient is referred for imaging first and then a biopsy is performed by the mammography 
department.  
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This process will identify patients with loco-regional recurrence as the patients may re-present to the 
breast centres with a breast or an axillary symptom and then referred to the mammography 
department. Patients with distant recurrence may present to other disciplines for their symptoms. A 
pleural effusion might manifest as shortness of breath and be managed by the Pulmonology 
department; similarly a patient with bone metastases might present with back pain and therefore be 
investigated and managed by the orthopaedic department and initially bypass the breast centres.  
The specimen number and hospital number were then cross checked on the National health laboratory 
system (NHLS) pathology system to ascertain whether recurrence was confirmed and whether 
hormone receptor status was available for matching primary and recurrence.  
Only the receptor status of matching primary and recurrence were recorded on a data sheet (Appendix 
2) and numbered chronologically. Patient’s personal details were not recorded on the data sheet and in 
the study. 
Those patients in whom hormone receptor status could not be confirmed for both primary and 
recurrence were not included in the study. 3 patients were recorded as having breast cancer 
recurrences but no histology of the primary tumour could be found. 
Oestrogen receptor(ER) status, progesterone receptor (PgR) status and human epidermal growth 
factor type 2 (HER2) statuses were noted for each patient and a comparison was made between 
primary, and recurrence, with loss and gain being noted. 
Oestrogen and progesterone receptors were tested for by means of immune-histochemistry (IHC) at 
primary and recurrence. The intensity of the hormone receptor status was not taken into account. Any 
positive receptor result, weak or strongly positive was noted as positive, similarly with the negative 
results, this was done because not all results identified intensity or strength and were simply labelled 
positive or negative. 
All HER2 receptors were tested by means of IHC, with results being labelled as negative (0 or 1+), 
equivocal (2+) and positive (3+). Those results which were equivocal would be subject to further 
testing by Fluorescent in Situ Hybridisation (FISH) to ascertain the true status. HER2 results which 
were equivocal and not submitted for gene copy analysis (FISH) were excluded. Due to the high 
expense of further testing, the additional testing might not have been undertaken especially during the 
period when Trastuzumab was not readily available in the State sector. 
Statistical analysis 
Receptor status was compared for each matched primary and recurrence. 
A change in receptor status was noted as discordance and an overall percentage of discordance was 
calculated. Details of change of receptor status were then documented for each receptor, noting a 
change from positive to negative, and vice versa. 
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Results  
 
Between 2006 and 2014, a total of 70 patients were found to fit the inclusion criteria. Of the 70 
patients, 1 patient did not have the HER2 receptor assessed in the primary breast cancer leaving 69 
HER2 receptors available for assessment.  
The oestrogen and progesterone hormone receptor status was assessed using IHC and was reported as 
being either weakly or strongly positive or negative. The intensity of each was not taken into account 
and was recorded only as either positive or negative. 
 
Table 1: Oestrogen receptor results 
Oestrogen Receptor Status Number 
 
Total number assessed 
ER Positive Primary 
ER Negative Primary 
ER Loss (proportion of Positive Primary) 
ER Gain (proportion of Negative Primary) 
Total Discordance 
 
 
70 
45(64.2%) 
25(35.7%) 
4(8.9%) 
6(24.0%) 
10(14.3%) 
  
  
  
  
 
A total of 70 Oestrogen receptors were assessed and it was found that 45 were positive and 25 were 
negative in the primary cancer. A total discordance in oestrogen status was observed in 10 cases 
(14.3%). Among the 45 positive primary receptors, 4 switched to negative at recurrence (8.9%) and 
41 maintained positivity. 6 of the 25(24%) negative primary receptors acquired positivity at 
recurrence.  
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Table 2: Progesterone receptor results 
Progesterone Receptor Status Number 
 
Total number assessed 
PgR Positive Primary 
PgR Negative Primary 
PgR Loss (proportion of Positive Primary) 
PgR Gain (proportion of Negative Primary) 
Total Discordance 
 
 
70 
34(48.6%) 
36(51.4%) 
11(32.3%) 
7(19.4%) 
18(25.7%) 
 
  
  
  
  
  
  
  
 
 
With regards to progesterone receptor status, 70 patients were included without exclusions and a total 
of 70 receptors were assessed, 34 positive primary receptors were noted and 36 negative primary 
receptors were noted. 11(32.3%) receptors “switched” from positive to negative at recurrence and 
7(19.4%) switched from negative to positive at recurrence, with a total discordance of 18(25.7%) 
receptors.  
It was found that of the 69 patients with available HER2 receptors, 18 patients had equivocal HER2 
results (2+) in either the primary or in the recurrence and only 3 equivocal results were submitted for 
further testing. Therefore 15 had to be excluded because FISH testing was not performed and the true 
status could not be ascertained. After exclusion the total number of patients assessed for HER2 
discordance was 54.  
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Table 3: Human epidermal growth factor type 2 receptor results 
HER2 Receptor status Number 
 
Total number assessed 
Excluded 
Her2 Positive Primary 
Her2 Negative Primary 
Her2 Loss(proportion of Positive Primary) 
Her2 Gain(proportion of Negative Primary) 
Total Discordance 
 
 
54 
15 
12(22.2%) 
42(77.8%) 
4(33.3%) 
4(9.5%) 
8(14.8%) 
  
  
  
  
HER2 positive : 3+     HER2 negative : 1+     
  
  
 
It was found that 12 receptors were HER2 positive at primary and 42 receptors were HER2 negative. 
Of the 3 that were submitted for FISH testing, 2 were concordant and 1 discordant. A change in 
receptor status was noted in 8 receptors (14.8%) with 4(33.3%) expressing a change from positive to 
negative and 4(9.5%) from negative to positive. 
 
In summary, the current study showed discordance in 10 ER receptors, 18 PgR receptors and 8 HER2 
receptors. 
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Chapter 4 
 
Discussion 
 
The recurrence of breast cancer is a life threatening event. Unless the recurrent disease is managed 
appropriately, the risk of breast cancer related mortality will increase. The treatment of breast cancer 
recurrence, in addition to local modalities such as surgery and radiation, requires systemic therapy. 
The latter includes cytotoxic drugs and therapies targeted to receptors within cancer cells. Of concern 
are the findings, widely reported in the literature, that the receptor profile of the primary cancer may 
have changed in the recurrence. This has serious implications for the selection of systemic treatment 
for the recurrent disease. 
 
Receptor Discordance 
 
In this study, it was found that of the 70 receptors assessed, there was a discordance of 10 (14.3%) 
oestrogen receptors (ER). Of the 10 cases which were found to be discordant, 6 expressed cytogenetic 
gain and 4 lost receptor sensitivity. These results are in keeping with available literature regarding ER 
discordance. A study by Dieci et al showed a discordance in ER receptors of 13.4% in 119 cases (16), 
similarly Broom et al showed that the discordance of ER receptors in their study of 100 patients was 
17.7 %( 22). A study performed by Nishimura et al showed that discordance in ER receptor did exist 
but to a lesser degree, with 10.3% of 97 patients (23). A meta-analysis of 48 articles performed by 
Aurelio et al showed a pooled discordance of ER receptor to be 20%. (24).  
The progesterone receptor has been the focus of investigation and its importance in regulation and 
modulation has been highlighted. A recent study published by Mohammed et al has described the role 
that progesterone may play. The study states that progesterone receptor expression is a biomarker of 
oestrogen receptor-α (ERα) function which in turn modulates tumour behaviour and is associated with 
a good clinical outcome. This is due to an increased sensitivity of the tumour to endocrine agents such 
as Tamoxifen and the aromatase inhibitors (25). Consequently, tumours which display PgR receptor 
negativity or a negative discordance at recurrence are less susceptible to anti-oestrogen therapy 
because of the lack of ERα and are therefore at risk of worse outcomes (25). 
Of the 70 PgR receptors assessed in this study, a discordance of 18 (25.7%) was noted, with 11 
receptors losing sensitivity at recurrence and 7 expressing receptor gain at recurrence. This is not out 
of keeping with relevant literature. In the same study quoted earlier, Nishimura et al showed 22% 
discordance in PgR (23). Higher discordance was noted in other studies. Broom et al and Aurelio et al 
both recorded discordance of 33.3 % in PgR receptors (22, 24). Higher rates of discordance was 
shown by Dieci et al and Karlsson et al, with rates of 39% and 40.7% respectively (16, 26).  
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During this study, difficulties were encountered during assessment of the HER2 receptors. 1 of 70 
patients did not have a HER2 result for the primary cancer. Of the remaining 69 cases, 18 results were 
equivocal at either primary or at recurrence. 3 of the 18 were submitted for further testing by in-situ 
hybridisation, 2 confirming concordant results and 1 discordant result. 15 cases were not submitted 
for in-situ hybridisation and therefore the results could not be confirmed and were excluded. The 
reason for this is uncertain but the extra cost of further testing may underlie this omission.  
Of the remaining 54 receptors, discordance was noted in 8 (14.8%) with 4 losing receptor sensitivity 
and 4 gaining sensitivity. Very similar to this result is that of Broom et al, who showed discordance in 
HER2 receptor status of 14.5% (22). Many other studies have displayed similar rates of discordance. 
Zidan et al, and Dieci et al showed discordance of HER2 to be 14% and 11.8% respectively (27, 16).  
Gangcberg et al exclusively used FISH testing results to assess HER2 status and showed a 
discordance of 7% in their study, similarly the meta-analysis performed by Aurelio et al showed a 
discordance of 8% for HER2 receptor status (28, 24). Even though 15 patients were excluded, the 
results of this study are quite comparable to the results found in relevant literature. If the equivocal 
results were submitted for confirmatory FISH testing, the accuracy of the results would be improved.  
 
Mechanisms of receptor change  
 
Receptor discordance may be the result of a genuine change in the bio-characteristics of the tumour. 
This is postulated to be due to clonal selection of a less differentiated receptor during the metastatic 
process (29).  The discordance may also result from intra-tumour heterogeneity, or possibly due to a 
lack of reproducibility and inaccuracy of the testing methods and assays used.  
Tumour heterogeneity describes a cancer with different tumour cell populations in the same patient 
and represents an unavoidable factor for accurate HER2 assessment (30). There are two main types of 
HER2 tumour heterogeneity, clustered HER2 amplification and mixed HER2 amplification. This 
disparity makes it difficult to accurately assess HER2 status and has led investigators to conceptualise 
and develop new novel methods to assess HER2 status with increasing accuracy (30). 
By definition, concordance of two results is the product of the accuracy of one testing method 
multiplied by the accuracy of another (31). Therefore, a 100% accurate test that is correct 100% of the 
time will have a 100% concordance. Similarly a 90% accurate test that correctly identifies the true 
receptor status 90% of the time would yield an 81% (0.9 x 0.9) concordance when repeated a second 
time on the same cases. This means 19% percent of receptor profiles could be discordant by chance 
alone. This illustrates how vital the accuracy and reproducibility of the testing methods and assays 
are. 
The study by Pusztai et al showed that differences in tissue fixation, antigen retrieval, and staining 
methods all contribute to variation in results. The subjective scoring of results dependant on the 
intensity of a stain by different pathologists also led to less than perfect inter-observer reproducibility 
(31).  
 
 
16 
 
 
Significance of Change 
 
Whether discordance represents a real change in tumour biology or a laboratory error, the results of 
the tests will have management implications for the patients undergoing testing. A “switch” from 
negative hormone receptors in the primary to positive receptor status in the recurrence may afford the 
patient the use of valuable adjuvant hormonal therapy. Conversely a “switch” from a receptor positive 
primary to a receptor negative recurrence identifies patients who are at an increased risk of 
unfavourable outcomes because hormonal therapy would not be indicated as adjuvant therapy and it 
also suggests that, due to the selection of aggressive tumour cell clones, the recurrence is more 
aggressive than the primary. This is supported by Lower et al which showed that patients with 
tumours that switched from a positive primary to a negative recurrence experienced significantly 
shorter median survival {669 days, p < 0.05} (32). Similarly Dieci et al during their study showed that 
the same positive to negative “switch”, translated into a worsened overall survival and prognosis 
compared with the corresponding concordant-positive cases (16). 
Discordance may also identify those patients, when the primary cancer was falsely negative, and who 
then presented with a recurrence found to be receptor positive. This would mean that the patient 
missed the opportunity of receiving hormonal therapy between the two events. One method of 
improving testing accuracy is to use the Bayesian misclassification correction method. Sighoko et al 
applied this method to a data set of 35000 patients from the SEER database and found that 34% of ER 
“conversion” and 17% of PgR “conversion” was due to technical misclassification (33). Another 
method of improving the accuracy of results may lie in the standardization of receptor profiling within 
a central laboratory (32). 
The results of this study were consistent with results described in literature (15, 16, 22, 23). The 
greater part of discordance was due to a receptor loss, chiefly the progesterone receptors. This would 
therefore identify patients at risk of worse outcomes. Where the treatment is unnecessary, the side 
effects of that treatment would be avoided. 
Conversely, those cases where there is cytogenetic gain of receptor sensitivity will benefit from the 
addition of targeted treatments.  
The aim of personalized medicine is to select therapy based on the basis of the molecular and genomic 
features of each individual tumour (34, 35).For this reason, re-profiling recurrent breast cancer 
assumes a major role.  
Central laboratories where measurements of hormone receptors and HER2 receptors follow the 
guidelines established by the American Society of Clinical Oncology and the American Society of 
Pathology add greater value to check the accuracy of assays done in peripheral laboratories (36). 
These centres are mostly only available in the well resourced Western centres (36). 
 
Conclusion 
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These results support the phenomenon of receptor discordance between breast cancer primary and its 
matched recurrence. It emphasizes the necessity of reassessing receptor status on all recurrent disease 
to identify discordance and facilitate appropriate systemic treatments.  
There seems to be many factors at various levels which may play a role in receptor discordance. By 
creating a standard format of sampling and testing, patients who undergo true biologic discordance 
would be identified and this would also limit the amount of discordance associated with inaccurate 
sampling and testing methods. 
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Appendix 2 : Data sheet 
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1. Rationale 
Breast cancer recurrence is a major clinical manifestation and represents a principal cause of breast 
cancer related death. The advent of hormone receptor sampling has significantly affected the 
management of breast cancer. The presence of Oestrogen(ER) and Progesterone (PgR) receptor 
positivity in breast cancers have been associated with improved prognosis. Receptor screening is 
performed on all biopsy specimens at initial presentation to determine sensitivity and in the event of 
recurrence to confirm sensitivity.   
This study aims to illustrate the rate of hormone receptor sensitivity discordance in patients with a 
loco-regional breast cancer recurrence. 
2. Introduction 
 
2.1. Background 
 
Breast cancer is the second most common cancer diagnosed worldwide with 1.67 million new cancer 
cases diagnosed in 2012 (25% of all cancers) (1).   
In South Africa, according to the 2005 cancer registry breast cancer is the most commonly diagnosed 
cancer among women, with a lifetime risk of 1:33. 
Breast cancer ranks second as a cause of cancer death in women (after lung cancer), and from 2005 to 
2009, rates decreased 3.0% per year in women younger than 50 and 2.0% per year in women 50 and 
older. The decrease in death rates represents progress in earlier detection, improved treatment, and 
possibly decreased incidence as a result of declining use of hormonal therapy (3, 4).  
The 5-year relative survival rate for female invasive breast cancer patients has improved from 75% in 
the mid-1970s to 90% today (5). 
 
2.2. Risk factors   
Women, regardless of their racial or ethnic origin, are at risk of developing breast cancer. Variations 
in breast carcinoma incidence rates among multicultural populations suggest that etiologic factors 
differ in their expression and impact on disease outcome (6). 
Key among those factors that affect breast carcinoma development is the roles of genetics and the 
environment, the reproductive experience and the effects of endogenous and exogenous hormones. 
The most significant risk factors  for breast cancer development are gender (female gender), age and 
female hormone exposure (7).  Gender is the most important factor, with a female to male ratio of 
100:1 (7). The incidence of breast cancer increases rapidly after the 4
th
 decade and after menopause 
the incidence continues to increase but at a much slower rate peaking in the 5
th
 and 6
th
 decades and 
then slowly levelling off (7).  
Family history of breast cancer is known to increase the risk of breast cancer. The overall risk 
depends on the number of relatives, their ages at diagnosis and whether the disease was unilateral or 
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bilateral (7). The highest risk is a young first degree relative with bilateral disease. About 5-10% of 
breast cancers can be linked to genetic mutations  inherited from one’s mother or father (8).  Women 
with a BRCA1 mutation have a 55-65% risk of developing breast cancer before age 70 and women 
with a BRCA2 mutation, have a  risk of 45% (9).  
Other risk factors implicated in breast cancer development include hormone exposure, whether 
endogenous or exogenous, age of menarche, age at initiation of regular menstrual cycles, age at first 
pregnancy and age of menopause all contribute to developing breast cancer. During the Women’s 
Health Initiative, exogenous hormone exposure, in the form of menopausal hormonal therapy was 
shown to increase the risk of developing breast cancer over a 5 year period by 26%  (10, 11)  
2.3. Recurrence  
A pattern of recurrence between different breast cancer subtypes has been suggested, and it appears 
that ER-negative breast cancers are associated with a higher risk of recurrence during the initial 5 
years after diagnosis, compared to ER-positive breast cancers (12, 13). Thereafter, the risk of 
recurrence steadily increases in ER-positive breast cancers for the next 10 years, and at 15 years 
following diagnosis, the risk appears to be equal for both sub-types(14). The triple negative cancers 
are generally associated with a high risk of recurrence with a particularly high risk of distant 
metastases, compared to receptor positive tumours (15). Apart from hormone receptor status other risk 
factors associated with loco-regional recurrence include the size of tumour, margin involvement at 
excision, axillary lymph node status and the nuclear grade and differentiation of the tumour.(16) 
 
2.4. Treatment 
The goals of breast cancer surgery include the complete resection of the primary tumour, with 
negative margins, to reduce the risk of local recurrences, and pathologic staging of the tumour & 
axillary lymph nodes to provide necessary prognostic information. Adjuvant treatment for breast 
cancer involves radiation and systemic therapy (chemotherapeutic, hormonal and biologic agents).  
Adjuvant treatment is designed to treat micro-metastatic disease and is aimed at reducing the risk of 
future recurrence, thereby reducing breast cancer-related morbidity and mortality. Knowledge of the 
oestrogen receptor(ER), progesterone receptor(PgR) and the Human Epidermal Growth factor type 2 
receptor(HER)2 status is fundamental for treatment selection among not only patients with early stage 
disease but also for those with metastatic disease.  In ER-positive early-stage breast cancer, hormone 
therapy plays a major role in adjuvant treatment, either alone or in combination with chemotherapy. 
Hormone treatments function to decrease oestrogen's ability to stimulate existing micro-metastases or 
dormant cancer cells (17).   
 
A recent study by Lindstrom et al has demonstrated a discordance rate between receptor status 
between primary and recurrences of 32.4%, 40.7%, and 14.5% for ER, PgR and HER2 respectively 
(18).  
This change in receptor status translates into a worsened prognosis if the receptor has changed 
negatively or an improved prognosis if receptor change is positive (19). With such a large discordance 
rate between primary and recurrence, it would seem prudent for all possible breast cancer recurrence 
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to be re-staged and evaluated on its own merit and not treated or managed as its matched primary 
tumour. This may potentially lead to an improved survival and outcome. 
The basis of this study is to examine the discordance rate in hormone receptor status between matched 
primary and recurrent breast cancers within 2 Gauteng based breast units. 
 
2.5. This project in context: Comparison to literature on the topic 
 
Breast cancer management is guided by hormone status 
20% to 30% of the patients with early breast cancer will eventually relapse (20). In particular, breast 
cancer patients with loco-regional recurrence have been found to have 5-year disease-free survival 
rates of 13%–37% and overall survival rates of 21%–50% respectively (21-23). 
Hormone therapy remains the mainstay for hormone receptor–positive breast cancer. The decision for 
hormone treatment has traditionally relied on assessment of ER and PgR status of primary tumours, 
with the response generally related directly to ER and PgR content. Patients with ER– and PgR– 
tumours show virtually no response, whereas patients with breast cancers positive for both hormone 
receptors demonstrate a significantly higher response (24).  
Results and studies have shown that cancer receptors change between primary and recurrence 
Broom et al described significant discordance in receptor status between primary and recurrent breast 
pathology samples. A change in ER status occurred in 17.7% of patients (switching occurred both 
from ER-positive to -negative and vice versa) and for PgR it occurred in 37.3% of patients (all 
tumours lost PgR). This meant that a total of 45.1% of patients had some sort of hormone receptor 
change (25).  
Addition of hormone therapy increases survival and if hormone negative, has a worse prognosis 
Dieci et al. highlighted the prognostic effect of discordance between matched primary breast cancer 
and recurrence. Within the discordant group, a loss of a receptor expression rather than gain resulted 
as the main determinant of poor prognosis (18). In fact, patients who changed their tumour phenotype 
to triple negative by losing hormone receptor and/or HER2 expression experienced the shortest post 
recurrence survival and overall survival when compared with concordant cases (18). Moreover, when 
the impact of single-receptor change was evaluated, ER loss, PgR loss and HER2 loss was associated 
with a worse post recurrence survival and overall survival (consistently with previous large 
retrospective reports) (4,26-30)  Also ER-positive/PgR-negative metastatic tumours tend to have a 
more aggressive course and are associated with a reduced overall survival compared to those retaining 
PR (4, 28). As a result it has been recommended that hormone receptor and HER2 status should be 
determined for recurrences, any change identified may enlarge treatment possibilities for the patient 
and improve selection for targeted therapies. This is particularly important for loco-regional 
recurrence after mastectomy, which carries an unfavourable prognosis with high risk of distant 
metastases (31).  
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3. Study Objectives 
 To evaluate hormone receptor status in primary and recurrent loco-regional breast 
cancer patients in 2 Johannesburg specialist breast cancer centres. 
 To compare hormone receptor status between matched breast cancer primary and 
loco-regional recurrence. 
4. Methods 
Design :  cross sectional, descriptive,  observational study. 
Site of study : Helen Joseph hospital and Charlotte Maxeke Academic hospital   
Study population: All patients who presented to the above mentioned breast clinics with 
histologically proven loco-regional breast cancer recurrences.  
Sampling: Sampling will not be needed as the entire population will be included (mentioned above). 
The database at Helen Joseph begins in 2006, therefore patient results will be accumulated from then 
till 2014 for both hospitals. Based on the four months spent working at the Helen Joseph Breast ward 
an estimate of between 40 and 70 patients will be accrued. . The data will be obtained retrospectively 
from the patient files. The National Health Laboratory Service database will be used to confirm 
histology results. 
 
 Inclusion criteria :All patients at the above mentioned breast units with histologically confirmed 
loco-regional breast cancer recurrence, that have available hormone receptor sensitivity for both 
primary and recurrence will be included in this study.  
 Exclusion criteria: Patients with NHLS data and identification data which cannot be reconciled will 
be excluded.  
Measuring tool: A data collection sheet detailing the hormone receptor status of matching primary and 
recurrence for every corresponding patient will be used and labelled addendum A. 
Data collection: The mammography departments at both hospitals keep records of every patient who 
has undergone a breast biopsy. All patients detailed to have had a repeat biopsy for a possible 
recurrence were identified and added to a list. The histology results of all patients on the list were 
checked and those with available hormone receptor results were earmarked. The hormone receptor 
status for all primary and recurrent breast cancer as well as the corresponding patient number will be 
noted and entered onto the data sheet. A comparison can then be made between primary and recurrent 
receptor status. 
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5. Data analysis and statistics 
The study is purely descriptive; hence pie charts and tables will be used to graphically illustrate the 
results of the study. Because no comparisons will be made, no tests will be necessary. 
6. Ethics 
 
Ethics clearance number M150771 
 
6.1. Data safety 
Apart from histology results, no other personal details will be recorded and patients will remain 
anonymous for the duration of the study. 
 
 
7. Budget 
Funding will not be needed as the study is retrospective in nature and will only require access to the 
various databases. 
8. Anticipated problems 
None. 
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9. Timing 
 
 
 
 
 
 
 
 
 
 
 
Month of the 
Year 
Jan Feb March April 
May-
July 
Aug-
Oct 
Nov-
March 
April 
May-
June 
Literature search          
Reading 
literature 
         
Summarising 
literature 
         
Preparing 
Protocol 
         
Protocol 
Assessment 
         
Ethics 
application 
         
Collecting data          
Data analysis          
Writing up thesis          
Submit: marking          
Writing up paper          
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